The FDA has approved revised warnings for Amgen's Aranesp and Epogen and Johnson & Johnson's Procrit after new findings from a breast cancer study revealed that the anemia drugs "shortened overall survival" and may cause accelerated tumor development. An advisory panel is set to meet Thursday to assess the advantages and risks of the drugs, which are indicated for use in patients with kidney failure or who are on chemotherapy.

Full Story:
USA Today, Bloomberg

Related Summaries